Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


CSPI on kava

This article was originally published in The Tan Sheet

Executive Summary

FDA's request for healthcare practitioner data linking botanical with hepatotoxicity "in and of itself is not sufficient to protect consumers," Center for Science in the Public Interest says in Jan. 28 letter. Agency should request manufacturers, retailers to temporarily halt sales pending FDA determination of safety issues. "FDA should also issue an advisory to consumers explaining the concerns that have been raised and advise them to consult with their physicians before taking any products that contain kava," group maintains...





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts